International study on low-grade primary central nervous system lymphoma Journal Article
| Authors: | Jahnke, K.; Korfei, A.; O'Neill, B. P.; Blay, J. Y.; Abrey, L. E.; Martus, P.; Poortmans, P. M. P.; Shenkier, T. N.; Batchelor, T. T.; Neuwelt, E. A.; Raizer, J. J.; Schiff, D.; Pels, H.; Herrlinger, U.; Stein, H.; Thiel, E. |
| Article Title: | International study on low-grade primary central nervous system lymphoma |
| Abstract: | Objective: The aim of this study was to characterize the clinical presentation, course, and outcome of low-grade primary central nervous system lymphoma. Methods: Cases were assessed in a retrospective series collected from 18 cancer centers in 5 countries. Results: Forty patients (18 men, 22 women; median age, 60 years [range, 19-78]) were identified. Involvement of a cerebral hemisphere or deeper brain structures was seen in 37 patients, only leptomeningeal involvement in 2 patients, and spinal cord disease in 1 patient. Chemotherapy/radiotherapy was conducted in 15 patients, radiotherapy alone in 12, chemotherapy alone in 10, and tumor resection alone in 2, whereas 1 patient received no treatment. The median progression-free, disease-specific, and overall survival were 61.5 (range, 0-204), 130 (range, 1-204), and 79 (range, 1-204) months, respectively. Only age 60 years or older was associated with shorter progression-free (p = 0.009), disease-specific (p = 0.015), and overall survival (p = 0.001) in multivariate analysis. Interpretation: Low-grade primary central nervous system lymphoma differs from the high-grade subtype in its pathological, clinical, and radiological features. It has a better long-term outcome than primary central nervous system lymphoma in general with age 60 years or older adversely affecting survival. © 2006 American Neurological Association. |
| Keywords: | adult; clinical article; treatment outcome; aged; middle aged; survival analysis; survival rate; retrospective studies; clinical feature; disease course; doxorubicin; combined modality therapy; cytarabine; methotrexate; rituximab; magnetic resonance imaging; cancer grading; disease association; carboplatin; etoposide; cyclophosphamide; vincristine; age factors; retrospective study; ifosfamide; lomustine; procarbazine; thiotepa; vinblastine; central nervous system neoplasms; cancer center; brain; disease progression; lymphoma; bleomycin; multivariate analysis; vinca alkaloid; corticosteroid; teniposide; spinal cord disease; international cooperation; hemisphere; brain lymphoma; nitrosourea derivative; leptomeninx; brain radiography |
| Journal Title: | Annals of Neurology |
| Volume: | 59 |
| Issue: | 5 |
| ISSN: | 0364-5134 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2006-05-01 |
| Start Page: | 755 |
| End Page: | 762 |
| Language: | English |
| DOI: | 10.1002/ana.20804 |
| PUBMED: | 16586496 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 20" - "Export Date: 4 June 2012" - "CODEN: ANNED" - "Source: Scopus" |
